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INTRODUCTION
In radiotherapy, various tumor and
normal tissue characteristics affect the treatment
prescribed for an individual patient. Physical dose
is one of predictors of" response which can be
accurately measured. However, physical dose
distribution is not the only factor which determines
biological response of tumors and normal tissues.
Radiobiological response to physical dose vary as
a function of dose per fraction [Withers et ai,
1988; Withers et ai, 1983]. Models of biological
response of tumor and normal tissues to radiation
treatment can be a useful tool for evaluation of 3D
dose distributions and optimization of radiation
therapy [Goitein, 1987; Goitein and Niemierko,
1988; Niemierko and Goitein, 1991; Niemierko
and Goitein ].
Inevitable inhomogeneity of the dose
distribution causes importance of volume factor
and dose-volume histograms (DVH) as a useful
tool for treatment planning. While accurate
measurement and calculation of physical dose
distribution within the treatment volume is always
an important step of treatment planning, radiation
therapy could ultimately be better served by an
additional information received from the DVHs
which account for varying tissue sensitivity for
change in dose per fraction.
The aim of this paper is to provide a
simple method for employing information on
variation in tumor and normal tissue sensitivity for
change in fractionation parameters to biologically
normalized dose-volume histograms (BNDVH)
using linear - quadratic formula. The L-Q formula,
which is an essential component of this model, is
already well known, but the proposed application
is new. The BNDVH concept can be used for
evaluation of competing dose distributions and do
not require time consuming calculation of the
entire 3-dimensional dose distribution.
MATERIAL AND METHODS
Despite the recent advances in
technology of computers and imaging devices,
the conventional 3-dimensional treatment
planning is still a very time consuming process.
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More (valuable) information regarding treated
patient (such as CT, MRI or USG images) means
more data which has to be extensively processed.
Three-dimensional dose calculation is much
slower then it is for 2-dimensional cases, not only
because there are approximately two orders of
magnitude more points to calculate dose at, but
also, because good, 3D algorithms take
advantage of this extra information about 3D
geometry and 3D scatter effects. Computer
optimization of 3D dose distribution is still a very
time consuming process.
The computational burden associated
with 3-dimensional treatment planning can be
substantially reduced when one realizes that for
evaluation and assessment of treatment plans
there is no need to calculate dose within entire
volume defined by CT slices. "It is sufficient when
dose distributions and derived information such as
dose-volume histograms, dose statistics and
estimates of tumor control probability and normal
tissue complication probabilities are calculated
over selected volumes of interest [Niemierko and
Goitein, 1991; Niemierko and Goitein]. These
volumes of interest are target(s), organs at risk
and eventually other structures which should be
taken into account. As we elaborated elsewhere,
calculating of dose at points randomly positioned
inside each volume of interest (instead of using
rectangular matrix of points) can further reduce
the number of calculational points at least tenfold
without decreasing accuracy [Niemierko and
Goitein, 1990]. For most clinical cases we use
400 randomly positioned points per volume of
interest. For unusually large and geometrically
complex structures, less points is generated
according to formula that the average distance
between calculational points do not need to be
less then 2mm [Niemierko and Goitein].
The clinical usefulness of dose-volume
histograms for 3D treatment planning has been
proven [Chen, 1988; Shipley et ai, 1979]. In
constructing DVH we use an approach we term
volume-dose distribution. This is a cumulative
distribution whose computed points are equally
spaced in the volume rather than dose dimension.
It is computed by sorting the calculational points in
order of decreasing"dose, and then plotting dose
7
Maciejewski et a/.: Concept of biologically normalized dose-volume....
versus point index number multiplied by the
average volume per point. Using this approach,
no information is lost (regular DVH is constructed
by binning points, i.e., information is averaged
over a set of points composing an each bin) and it
can be used even for a small number of points
[Niemierko and Goitein, 1991; Niemierko and
Goitein ].
Dose-volume histograms are a useful
treatment planning tool because dose
distributions within volumes of interest are
inhomogeneous (if they were homogeneous, one
number would completely describe the dose
distribution). Biological response of a particular
organ depends, however, not only upon details of
the dose-volume distribution but also upon the
way the dose was delivered i.e. upon the
fractionation scheme. Therefore, it seemed to us
that a concept of DVH including an extra
information regarding tissue sensitivity (through a
and p parameters of the linear - quadratic model)
and fractionation scheme (through number of
fractions or dose per fraction) would be a helpful
tool when evaluating various treatment plans.
According to the linear - quadratic model
[18] the (cellular) effect of every fraction (partial
effect) can be expressed as a product of physical
dose d and fractionation factor:
- (1)
When total dose D is delivered in N fractions (not
necessarily of equal dose) the total effect is a sum
of partial effects:
- (2)
The same effect can be achieved when dose
is delivered in equal fractions of 2Gy up to the
biologically .equivalent, unknown dose BNDz
(which stands for Biologically Normalized Dose):
- (3)
Equation (3) is an iso-effect equation
which allows calculating physical dose BND
delivered in equal fractions of 2Gy, equivalent (in
terms of the same fraction of surviving cells) to
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We normalize dose to equivalent dose
delivered in equal fractions of2Gy but, of course,
normalization to a different dose per fraction can
be used. We use 2Gy because most published
dose-response curves are obtained (or
recalculated) for this dose per fraction
[Maciejewski, 1991; Macieje)Nski et ai, 1989;
Withers et ai, 1984].
When all N fractions ale equal (to dose d)
the equation (4) reduces to simpler form:
a d-2 a




It is obvious from equation (5) that
fractionation effects (expressed through
normalization factor NF) are larger for tissues and
endopoints with smaller a113 ratio and that the
absolute effect (i.e. expressed in Gy) of
fractionation different than 2 Gy per fraction is
linearly proportional to the total dose D. We would
like to emphasize that BND is not a biological
dose or. a measure of biological effect. It is a
physical dose expressed in dose units (Gy) which
gives the same cell survival fraction as dose D
given in egualfractions of 2 Gy.
Equations (4) or (5) can be directly used
to recalculate value of every bin of the DVH (i.e.
dose at each calculational point in our volume-
dose distribution). The resulting product we call
Biologically Normalized Dose-Volume Histogram
(BNDVH) as it contains not only information about
dose-volume distribution but also takes into
account sensitivity of irradiated organ (through a/l3
value) and fractionation scheme (through number
of fractions and dose per fraction).
RESULTS
Example 1
To demonstrate the influence of
fractionation effects on the BNDVH for tumor and
normal tissues we choose the case qualified to
the proton therapy at the MGH in Boston. The
spinal cord was very close to the tumor and
partially within the irradiated volume. The BNDs
were calculated for 20, 30, 40 and 50 fractions
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regimens using the alP rations of 15 Gy for tumor
and of 2.0 Gy for spinal cord [Maciejewski et ai,
1989; Williams et ai, 1985].
volume. In contrast, for 40 - 50 fraction regimens,
100% of irradiated volume would receive the BND





















The case of abdominal tumor irradiated
with 35 Gy of total dose using large abdominal
fields including whole kidney without partial
shielding was chosen and the BNDVH for kidney
was constructed using an alP equal to 1.6 Gy
[Williams et ai, 1985]. Figure 2 shows BNDVHs
calculated for the same fractionation regimens as
were used for example 1. The BNDVH for
physical dose (solid line) shows that 20% of the
volume would receive a total dose exceeding 25
Gy. However, when a various fractionation
schedules are accounted for, it is seen that 100%
of kidney volume receives the equivalent BND
smaller than 25 Gy.
Kidney
Spinal Cord

































Fig. 1 Physical (solid line) and biologically normalized dose-
volume histograms (BNDVH) for 4 fractionation schemes for
target (Fig. 1 A) and spinal cord (Fig. 1 B).
Fig. 2 Physical (solid line) and biologically normalized dose-
volume histograms (BNDVH) for 4 fractionation schemes for
kidney.
DISCUSSION
BNDVHs for tumor and spinal cord were
constructed using expression (5). Figure 1a
shows the BNDVH for the tumor and Figure 1b
for the spinal cord. For tumor, each value of alp of
above 15 Gy does not greatly modify the BND
value (1 - 4% increase in the BND). Figure 1a
shows that 100% of tumor volue receives a total
dose of at least 60. Gy, regardless of fractionation
schedule.
Assuming the TCD90 dose of 66. Gy ,
this dose is given to about 90% of the tumor
volume. Within 10% of the tumor volume, the
choice of 20 - 30 fraction regimens would change
an effective biological dose of about 10%,
whereas if a larger number of fractions is chosen,
no more than 5% change in effective biological
dose is observed.
For the spinal cord (Figure 1b), BNDVH
shows that 20% of the irradiated spinal cord
receives more than 50 Gy. If 20 fractions would
be given, the BND higher than 50 Gy will be
delivered to more than 30% of the irradiated
The presented method of calculating the
biologically normalized dose-volume histograms
(BNDVH) is a simple and easy to use in practice.
The most important aspect of the proposed
method is that BNDVHs are a better tool for a
comparsion of various treatment approaches and
fractionation schedules than dose distribution
display because, even if all fields are treated the
same day the isoeffect lines follow the isodose
lines only within the same structure (or tissue
characterized by the same alP).
The presented analysis shows, at the first
glance, a relatively small of fractionation effects
on the shape of the BNDVH for tumor. However,
it may depend on the choice of TCD dose level. If
60 Gy would be the prescribed TCD90 then the
BNDVH variations shown in the Figure 1 are
insignificant for tumor control probability because
100% of the tumor volume receives that dose:
Assuming that 9 logs cell killing is required for
local tumor control (p cure = 0.9) and that the
Rep. Pract. Oncol. 1 (1) 1996 9

















Assuming that 50 Gy given in 2 Gy fractions
cause 0.2% risk for spinal cord, Figure 5 shows
that 20 fraction regimen is unacceptable because
of a high risk of late myelopathy. Among the
tested fractionation regimens, only 50 fractions
can be considered as a low risk treatment.
Fig. 4 Risk dose curves for late kidney atrophy and spinal cord
myelopathy estimated from clinical data [Glatstein, 1973;
Maciejewski, 1991; Schultheiss, 1990; Withers et ai, 1983]
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and Steckel [Steckel et ai, 1974] have found, that
even heavy damage of 50% of kidney volume
does not reveal clinical dysfunction (due to
compensatory function of the remaining 50% of
kidney).
Risk dose (RD) curves (FigA) for spinal
cord and kidney estimated from clinical data
[Glatstein, 1973; Maciejewski, 1991; Schultheiss,
1990; Withers et ai, 1984] by logistic regression
[Walker and Suit, 1983] were used to convert the
BNDVHs into the risk curveS plotted against the




















TCD90 is 66 Gy, the dose D10 necessary to
reduce the cell survival by 1 logarithm to 10%
would be 66/9 =7.3 Gy and the change in total
effective dose of an average of 10% would
correspond to one log10 and it would result in a
change in local control of about 10 - 15%. Figure 1
shows variations in total dose of about 3.5 Gy - 7
Gy within 20% of tumor volume which may
cause a decrease in the probability of local tumor
control (Fig. 3) and an increase of the risk of local
failure. This example implies that the prediction of
local tumor control probability depends on a
chosen level of the TeD and biological
characteristics of an individual tumor and then,
even a small variations in the BNDVH should not
be ignored.
Fig. 3 Tumor control probability versus treatment volume
from the BNDVHs in Fig. 1 A assuming TCD 90 = 66Gy and
that 9 logs cell killing is required for TCP =0.9.
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Many authors have offered models of
complication probability as a function of dose and
irradiated volume. Lyman and Lyman and
Wolbarst [Lyman,1985; Lyman and Wolbart,
1988] proposed a 3-parameter model where the
complication probability is expressed as an error
function and a power law describes a dose-
volume relationship. The dose response curve for
late effect in normal tissue and its steepness
varies as a function of volume [Withers et ai,
1988] and tolerance can not be viewed or
expressed simply as a function of dose. The risk
of complications depends on the organization and
size of the respective functional subunits - FSU
[Withers et ai, 1988; Withers et ai, 1993]. We
have constructed the BNDVHs for two organs, Le.
spinal cord and kidney to compare the effect of
different organization of the FSUs in these
organs: the spinal cord has a series organization
and FSUs in kidney (nephrons) are organized
parallelly. In the spinal cord the damage of a
single FSU causes a fatal late complication
(myelopathy) whereas Glatstein [Glatstein,1973]
10 Rep. Pract. Oneal. 1 (1) 1996
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While from the clinical point of view even
1% risk for spinal cord damage is unacceptable,
for kidney, severe damage of the 50% of its
volume may functionally be compensated by the
remaining undamaged volume of this organ.
Ffgure 5 shows for kidney that risk probability
curves for each of the analyzed fractionation
regimens give a tolerable risk of a functional
failure of the kidney.
Presented examples illustrate how the
BNDVH can be interpreted to choose the optimal
physical dose distribution and the best
fractionation scheme. The BNDVHs may provide
an important information for optimization of
radiation treatment planning especially with
regards to the estimation of the risk of late effect
for normal tissues. It should be emphasized that
BNDVHs can be calculated and treatment plan
can be evaluated before the complete 3D dose
distribution is calculated. It is sufficient when dose
is calculated at a certain, relatively small number
of points generated only within the regions of
interest.
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